好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

An Altered Pontine-Hypothalamic Functional Interplay Could Predict Migraine Disease Progression Over the Years
Headache
P1 - Poster Session 1 (9:00 AM-5:00 PM)
475

To explore resting state (RS) effective connectivity (EC) abnormalities between the pons and hypothalamus in episodic migraine patients during the interictal phase and investigate their value in predicting migraine progression over the years.

Functional magnetic resonance imaging (fMRI) studies showed a significant interaction between the pons and hypothalamus during the pain phase of migraine. However, how these regions interact with each other during the interictal phase and whether the pontine-hypothalamic RS EC could influence migraine disease activity has never been investigated.

Ninety patients with episodic migraine and seventy-two controls underwent baseline interictal RS fMRI. Clinical evaluation was performed after a median of 4.5 years in 23 patients. RS EC of bilateral pons and hypothalamus was performed using SPM12 and dynamic causal modelling. RS EC differences between groups at baseline were investigated using parametric empirical bayes models. Linear regression models were used to identify imaging predictors of disease progression, as measured by changes in migraine frequency.

At baseline, compared to controls, migraine patients had (posterior probability>0.75) higher inhibitory EC within the left pons and from the right and left pons to the ipsilateral and contralateral hypothalamus. Migraine patients experienced also a lower inhibitory EC from the left hypothalamus to the left pons, as well as a lower excitatory EC from the right pons to the left pons. During the follow-up, 35% of patients reported an increased number of migraine attacks. Higher inhibitory RS EC from the left pons to the left (β=0.4, p=0.04) and right (β=0.5, p=0.02) hypothalamus predicted clinically worsening.

During the interictal phase, migraine patients experience a prominent inhibitory influence of the pons over the hypothalamus, while the inhibitory influence of the hypothalamus over the pons is reduced. A higher pontine-hypothalamic inhibitory activity may be a prognostic marker for migraine progression over the years.

Authors/Disclosures
Maria A. Rocca (Neuroimaging Research Unit)
PRESENTER
Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Roberta Messina, MD, PhD (San Raffaele Hospital) Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Organon. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly.
Paola Valsasina Paola Valsasina has nothing to disclose.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.